BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+12.44%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$7.87B
AUM Growth
+$7.87B
(+11%)
Cap. Flow
+$193M
Cap. Flow
% of AUM
2.46%
Top 10 Holdings %
Top 10 Hldgs %
73.35%
Holding
115
New
19
Increased
20
Reduced
44
Closed
6
Top Buys
| 1 |
ITMN
INTERMUNE INC
ITMN
|
$140M |
| 2 |
ACOR
Acorda Therapeutics, Inc.
ACOR
|
$37.9M |
| 3 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
$31.1M |
| 4 |
Heron Therapeutics
HRTX
|
$30.2M |
| 5 |
XNPT
XENOPORT, INC.
XNPT
|
$15.5M |
Top Sells
| 1 |
Arrowhead Research
ARWR
|
$38.7M |
| 2 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$35.1M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
$25.4M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$8.81M |
| 5 |
Halozyme
HALO
|
$7.61M |
Sector Composition
| 1 | Healthcare | 43.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
| $945M | 12.01% | 20,739,426 +3,500 | +0% | +$159K |
|
|
GEVA
2
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $883M | 11.23% | 10,648,182 +375,000 | +4% | +$31.1M |
|
|
PCYC
3
DELISTED
PHARMACYCLICS INC
PCYC
| $876M | 11.13% | 8,737,888 +18,670 | +0.2% | +$1.87M |
|
4
Incyte
INCY
$16.5B
| $794M | 10.09% | 14,835,559 +25,000 | +0.2% | +$1.34M |
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $498M | 6.33% | 20,481,442 +526,316 | +3% | +$12.8M |
|
|
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
| $360M | 4.57% | 13,654,150 +3,315 | +0% | +$87.3K |
|
|
ITMN
7
DELISTED
INTERMUNE INC
ITMN
| $145M | 1.84% | 4,324,843 +4,174,843 | +2,783% | +$140M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $128M | 1.63% | 1,883,230 -58,074 | -3% | -$3.96M |
|
9
Xoma
XOMA
$392M
| $120M | 1.53% | 23,057,572 +25,200 | +0.1% | +$131K |
|
|
ICPT
10
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $84.6M | 1.07% | 256,375 -106,472 | -29% | -$35.1M |
|
|
11
Halozyme
HALO
$8.56B
| $72.4M | 0.92% | 5,698,139 -598,887 | -10% | -$7.61M |
|
12
Vanda Pharmaceuticals
VNDA
$279M
| $72.2M | 0.92% | 4,445,696 -345,483 | -7% | -$5.61M |
|
|
13
BioCryst Pharmaceuticals
BCRX
$1.74B
| $62.1M | 0.79% | 5,867,031 -832,948 | -12% | -$8.81M |
|
|
ANAC
14
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $61.9M | 0.79% | 3,095,318 +595,318 | +24% | +$11.9M |
|
|
RPRX
15
DELISTED
Repros Therapeutics Inc.
RPRX
| $49.3M | 0.63% | 2,778,654 | – | – |
|
|
QCOR
16
DELISTED
QUESTCOR PHARMA INC
QCOR
| $46.6M | 0.59% | 717,745 -58,119 | -7% | -$3.77M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $45.4M | 0.58% | 2,380,074 | – | – |
|
|
DSCI
18
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $44.9M | 0.57% | 3,537,137 +978,280 | +38% | +$12.4M |
|
19
Cerus
CERS
$251M
| $40.6M | 0.52% | 8,455,306 | – | – |
|
20
Gilead Sciences
GILD
$140B
| $39.4M | 0.5% | 556,108 | – | – |
|
|
ACOR
21
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $37.9M | 0.48% | +1,000,000 | New | +$37.9M |
|
|
CHTP
22
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
| $37.3M | 0.47% | 6,760,394 +965,641 | +17% | +$5.33M |
|
|
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
| $36.7M | 0.47% | 529,990 -748 | -0.1% | -$51.8K |
|
|
24
Heron Therapeutics
HRTX
$207M
| $30.2M | 0.38% | +2,167,784 | New | +$30.2M |
|
|
AEGR
25
DELISTED
Aegerion Pharmaceuticals, Inc.
AEGR
| $23.7M | 0.3% | 513,922 +13,922 | +3% | +$642K |
|